Four centers

participated in all or parts of the E-MOSAIC-Feasibility-Study. Patients filled in the E-MOSAIC in a paper-pen and a palm version in random order. The compliance, time needed, and experiences of patients with the palm were assessed by a structured 2-page evaluation. 62 patients (median Inhibitors,research,lifescience,medical age 64y [30–85], 25 female) participated. 4 patients had visual impairment, 6 comprehension problems, and 1 pat was too tired. 3/62 patients did not complete E-MOSAIC. Median time to complete was 3minutes. 10 patients preferred paper and 28 palm, 16 had no preference; 50 patients agreed to continue using palm. Palm-based symptoms (VAS) were compared with a paper-based categorical selleck symptom assessment (ESAS). Wilcoxon signed-rank tests showed no significant differences between palm and paper of 9 symptoms Inhibitors,research,lifescience,medical of element P (p-value: well-being 0.089, dyspnea 0.060, the remaining 7 symptoms 0.249-0.940), but for nutritional intake different (a significant difference was found (.p=0.013). Test-retest (1hour, n=20) reliability of 9 symptoms and Inhibitors,research,lifescience,medical nutritional intake was satisfactory (Cronbach alpha 0.62 – 0.94). The E-MOSAIC intervention for this

6-week trial Although the E-MOSAIC incorporates a module offering the possibility for real-time measurement of clinical benefit response and showing it in the LoMoS the duration of this study of 6weeks treatment, classical clinical benefit

response will not be measured as an outcome, since it needs longer observation to fulfill the criteria. Patient population and Inhibitors,research,lifescience,medical setting Patients are eligible who receive anticancer treatment in palliative intention given weekly or biweekly or continuous in the outpatient setting, and routine care which typically includes weekly visits. The setting and routine processes Inhibitors,research,lifescience,medical of care include a personal professional nursing contact and a brief patient assessment before the patients visit at the oncologists. • The palliative intention of the anticancer Adenosine triphosphate treatment is defined as an expected tumor response rate≤20% according to literature. To operationalize this definition, a list of tumor types and treatment line was composed (e.g. second line non-small cell lung cancer). • Patients have to be symptomatic (symptoms measured by VAS: 0=best, 10=worst; average over last 24hours) by the cancer disease, defined as at least one ESAS symptom>= 3/10. • Patients have to be able to understand the language of the E-MOSAIC assessment and the study related information, written informed consent and the physician is able to communicate with the patient studied without major difficulties (i.e., culture, language, speech).